Patients with TPBC or ER+PR-HER2+ breast cancer were less likely to be diagnosed with node-positive disease (38.4% and 38.1%, respectively) than those with ER-PR-HER2+ breast cancer (42.3%). This evidence concerns the gene ERBB2 and breast carcinoma.